While questions remain surrounding the accessibility of lenacapavir, the drug holds greater potential for reducing the global incidence of HIV than any other to date, says GlobalData.
Tag Archive for: HIV
CVS Health has lost a bid to escape a proposed class action lawsuit accusing the company of discriminating against people with HIV by requiring them to receive their medications by mail.
The World Health Organization on Tuesday flagged growing HIV drug resistance against GSK and ViiV Healthcare’s antiretroviral medication Tivicay (dolutegravir), noting that observational and survey data suggest that resistance may now be higher than levels observed in clinical trials.
ViiV Healthcare and GSK’s Cabenuva in a Phase III study showed superior efficacy versus daily oral antiretroviral treatment in HIV patients with a history of difficulties in taking daily pills.
The company beat market estimates for fourth-quarter results today, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the benefits of its consumer health unit spin-off.
The regulator’s Complete Response Letter flagged issues with the new formulation of tesamorelin’s chemistry, manufacturing and controls and sought more information about its immunogenicity risk.
The British drugmaker said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines.
The claims allege that the drugmaker’s tenofovir, an antiretroviral used in Gilead’s older HIV drugs, caused kidney, tooth, or bone damage to patients, and that Gilead knew its tenofovir-based drugs which were still in development, were safer.
Today the company lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection.
Let’s think of this Barbie phenomenon as a catalyst to put women’s health and well-being at the forefront. How can we, as pharma marketers, keep the momentum going?